Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 17/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | GHSR | Q92847 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841767 | 0.93 | SCN9A (0.81) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL840393 | 0.91 | SCN9A (0.71) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841771 | 0.87 | SCN9A (0.87) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL840425 | 0.85 | SCN9A (0.83) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841958 | 0.84 | SCN9A (0.79) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841479 | 0.84 | SCN9A (0.87) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841780 | 0.83 | SCN9A (0.80) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841736 | 0.83 | SCN9A (0.77) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL841315 | 0.83 | SCN9A (1.00) | SCN9ASCN5AKCNH2CNR1SLC6A3 | |
| SCHEMBL840463 | 0.82 | SCN9A (0.78) | SCN9ASCN5AKCNH2CNR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | claimed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-2158198-B1 | N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | SCN9A 302/4885SCN5A 55/4885KCNH2 399/4885 |
| US-20120238579-A1 | New Compounds 806 | CYP2B6, CYP11B2, NDUFS6 | SCN9A 2285/4885SCN5A 380/4885KCNH2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.